|
1
|
Grunewald T and Ledermann JA: Targeted
therapies for ovarian cancer. Best Pract Res Clin Obstet Gynaecol.
41:139–152. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jaaback K, Johnson N and Lawrie TA:
Intraperitoneal chemotherapy for the initial management of primary
epithelial ovarian cancer. Cochrane Database Syst Rev.
1:CD0053402016.
|
|
3
|
Zsiros E, Tanyi J, Balint K and Kandalaft
LE: Immunotherapy for ovarian cancer: Recent advances and
perspectives. Curr Opin Oncol. 26:492–500. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shi C and Wang M: LINC01118 modulates
paclitaxel resistance of epithelial ovarian cancer by regulating
miR-134/ABCC1. Med Sci Monit. 24:8831–8839. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Papaevangelou E, Almeida GS, Box C,
deSouza NM and Chung YL: The effect of FASN inhibition on the
growth and metabolism of a cisplatin-resistant ovarian carcinoma
model. Int J Cancer. 143:992–1002. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen SH and Chang JY: New insights into
mechanisms of Cisplatin resistance: From tumor cell to
microenvironment. Int J Mol Sci. 20:E41362019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jin P, Liu Y and Wang R: STAT3 regulated
miR-216a promotes ovarian cancer proliferation and cisplatin
resistance. Biosci Rep. 38:BSR201805472018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ai Z, Lu Y, Qiu S and Fan Z: Overcoming
cisplatin resistance of ovarian cancer cells by targeting
HIF-1-regulated cancer metabolism. Cancer Lett. 373:36–44. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang C, Gao J, Yan N, Wu B, Ren Y, Li H
and Liang J: Propofol inhibits the growth and survival of gastric
cancer cells in vitro through the upregulation of ING3.
Oncol Rep. 37:587–593. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang N, Liang Y, Yang P, Yang T and Jiang
L: Propofol inhibits lung cancer cell viability and induces cell
apoptosis by upregulating microRNA-486 expression. Braz J Med Biol
Res. 50:e57942017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen X, Li K and Zhao G: Propofol inhibits
HeLa cells by impairing autophagic flux via AMP-activated protein
kinase (AMPK) activation and endoplasmic reticulum stress regulated
by calcium. Med Sci Monit. 24:2339–2349. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu B, Gao W, Zhou H, Miao X, Chang Y, Wang
L, Xu M and Ni G: Propofol induces apoptosis of breast cancer cells
by downregulation of miR-24 signal pathway. Cancer Biomark.
21:513–519. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang P, Chen J, Mu LH, Du QH, Niu XH and
Zhang MY: Propofol inhibits invasion and enhances
paclitaxel-induced apoptosis in ovarian cancer cells through the
suppression of the transcription factor slug. Eur Rev Med Pharmacol
Sci. 17:1722–1729. 2013.PubMed/NCBI
|
|
14
|
Kumar S, Boon RA, Maegdefessel L, Dimmeler
S and Jo H: Role of noncoding RNAs in the pathogenesis of abdominal
aortic aneurysm. Circ Res. 124:619–630. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu B, Li J and Cairns MJ: Identifying
miRNAs, targets and functions. Brief Bioinform. 15:1–19. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ma JB, Hu SL, Zang RK, Su Y, Liang YC and
Wang Y: MicroRNA-487a promotes proliferation of esophageal cancer
cells by inhibiting p62 expression. Eur Rev Med Pharmacol Sci.
23:1502–1512. 2019.PubMed/NCBI
|
|
17
|
He H, Zhao X, Zhu Z, Du L, Chen E, Liu S,
Li Q, Dong J, Yang J and Lei L: MicroRNA-3191 promotes migration
and invasion by downregulating TGFBR2 in colorectal cancer. J
Biochem Mol Toxicol. e223082019.doi: 10.1002/jbt.22308 (Epub ahead
of print). View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu H, Liu Y, Shu XO and Cai Q: MiR-374a
suppresses lung adenocarcinoma cell proliferation and invasion by
targeting TGFA gene expression. Carcinogenesis. 37:567–575. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goto T, Takano M, Hirata J and Tsuda H:
The involvement of FOXO1 in cytotoxic stress and drug-resistance
induced by paclitaxel in ovarian cancers. Br J Cancer.
98:1068–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang J, Yang H, Li W, Xu H, Yang X and Gan
L: Thioredoxin 1 upregulates FOXO1 transcriptional activity in drug
resistance in ovarian cancer cells. Biochim Biophys Acta.
1852:395–405. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li N, Yang L, Wang H, Yi T, Jia X, Chen C
and Xu P: MiR-130a and MiR-374a function as novel regulators of
cisplatin resistance in human ovarian cancer A2780 cells. PLoS One.
10:e01288862015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang L, Hu C, Chao H, Wang R, Lu H, Li H
and Chen H: miR-29c regulates resistance to paclitaxel in
nasopharyngeal cancer by targeting ITGB1. Exp Cell Res. 378:1–10.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yue ZX, Gao RQ, Gao C, Liu SG, Zhao XX,
Xing TY, Niu J, Li ZG, Zheng HY and Ding W: The prognostic
potential of coilin in association with p27 expression in pediatric
acute lymphoblastic leukemia for disease relapse. Cancer Cell Int.
18:1062018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ajabnoor GM, Crook T and Coley HM:
Paclitaxel resistance is associated with switch from apoptotic to
autophagic cell death in MCF-7 breast cancer cells. Cell Death Dis.
3:e2602012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gong S, Chen Y, Meng F, Zhang Y, Wu H, Li
C and Zhang G: RCC2, a regulator of the RalA signaling pathway, is
identified as a novel therapeutic target in cisplatin-resistant
ovarian cancer. FASEB J. 33:5350–5365. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li X, Zou Z, Tang J, Zheng Y, Liu Y, Luo
Y, Liu Q and Wang Y: NOS1 upregulates ABCG2 expression contributing
to DDP chemoresistance in ovarian cancer cells. Oncol Lett.
17:1595–1602. 2019.PubMed/NCBI
|
|
28
|
Norouzi-Barough L, Sarookhani MR, Sharifi
M, Moghbelinejad S, Jangjoo S and Salehi R: Molecular mechanisms of
drug resistance in ovarian cancer. J Cell Physiol. 233:4546–4562.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chidambaran V, Costandi A and D'Mello A:
Propofol: A review of its role in pediatric anesthesia and
sedation. CNS Drugs. 29:543–563. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fan W, Zhu X, Wu L, Wu Z, Li D, Huang F
and He H: Propofol: An anesthetic possessing neuroprotective
effects. Eur Rev Med Pharmacol Sci. 19:1520–1529. 2015.PubMed/NCBI
|
|
31
|
Zhang D, Zhou XH, Zhang J, Zhou YX, Ying
J, Wu GQ and Qian JH: Propofol promotes cell apoptosis via
inhibiting HOTAIR mediated mTOR pathway in cervical cancer. Biochem
Biophys Res Commun. 468:561–567. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu SQ, Zhang JL, Li ZW, Hu ZH, Liu Z and
Li Y: Propofol inhibits proliferation, migration, invasion and
promotes apoptosis through down-regulating miR-374a in
hepatocarcinoma cell lines. Cell Physiol Biochem. 49:2099–2110.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li H, Lu Y, Pang Y, Li M, Cheng X and Chen
J: Propofol enhances the cisplatin-induced apoptosis on cervical
cancer cells via EGFR/JAK2/STAT3 pathway. Biomed Pharmacother.
86:324–333. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qian J, Shen S, Chen W and Chen N:
Propofol reversed hypoxia-induced docetaxel resistance in prostate
cancer cells by preventing epithelial-mesenchymal transition by
inhibiting hypoxia-inducible factor 1α. Biomed Res Int.
2018:41742322018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang X, Teng Y, Yang H and Ma J: Propofol
inhibits invasion and growth of ovarian cancer cells via regulating
miR-9/NF-κB signal. Braz J Med Biol Res. 49:e57172016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhao C, Lu E, Hu X, Cheng H, Zhang JA and
Zhu X: S100A9 regulates cisplatin chemosensitivity of squamous
cervical cancer cells and related mechanism. Cancer Manag Res.
10:3753–3764. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
He W, Feng L, Xia D and Han N: MiR-374a
promotes the proliferation of human osteosarcoma by downregulating
FOXO1 expression. Int J Clin Exp Med. 8:3482–3489. 2015.PubMed/NCBI
|
|
39
|
Xu Y, Bei Y, Shen S, Zhang J, Lu Y, Xiao J
and Li X: MicroRNA-222 promotes the proliferation of pulmonary
arterial smooth muscle cells by targeting P27 and TIMP3. Cell
Physiol Biochem. 43:282–292. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Roy A and Banerjee S: p27 and leukemia:
Cell cycle and beyond. J Cell Physiol. 230:504–509. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li Y, Deng S, Peng J, Wang X, Essandoh K,
Mu X, Peng T, Meng ZX and Fan GC: MicroRNA-223 is essential for
maintaining functional β-cell mass during diabetes through
inhibiting both FOXO1 and SOX6 pathways. J Biol Chem.
294:10438–10448. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Suzuki R, Amatya VJ, Kushitani K, Kai Y,
Kambara T and Takeshima Y: MiR-182 and miR-183 promote cell
proliferation and invasion by targeting FOXO1 in mesothelioma.
Front Oncol. 8:4462018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li Y, Deutzmann A and Felsher DW:
BIM-mediated apoptosis and oncogene addiction. Aging (Albany NY).
8:1834–1835. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li L, Wang C, Wen Y, Hu Y, Xie Y, Xu M,
Liang M, Liu W, Liu L and Wu Y: ERK1/2 and the Bcl-2 family
proteins Mcl-1, tBid, and Bim are involved in inhibition of
apoptosis during persistent chlamydia psittaci infection.
Inflammation. 41:1372–1383. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Huang C, Chen D, Zhu H, Lv S, Li Q and Li
G: LITAF enhances radiosensitivity of human glioma cells via the
FoxO1 pathway. Cell Mol Neurobiol. 39:871–882. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Qin Y, Li L, Wang F, Zhou X, Liu Y, Yin Y
and Qi X: Knockdown of Mir-135b sensitizes colorectal cancer cells
to oxaliplatin-induced apoptosis through increase of FOXO1. Cell
Physiol Biochem. 48:1628–1637. 2018. View Article : Google Scholar : PubMed/NCBI
|
